The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...

In hepatitis B virus (HBV) infection, the capacity to mount a functional virus-specific T-cell response has long been considered the principal, if not the sole, immunological determinant of viral ...

Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent research, a team led by Dr. Armin Rehm presents an improved immunotherapy that ...

The immune cell repertoire is composed of many different cell types that are orchestrated in response to infection and other pathogens that enter the body. As a result, the body can defend itself ...

However, details of the intervening steps, as researchers have learned in the past 65 years, are quite complex — certain cells carry the flu antigen to the immune system, specific immune cells respond ...

Neoantigens are unique markers that distinguish only cancer cells. By adding B cell reactivity, cancer vaccines can move ...

Researchers have used an experimental mRNA therapy to make old immune cells in mice behave as if they were young again, ...

At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...